Details

Non-thermal ablation and drug delivery by electroporation : expanding current indications beyond cancer and cardiac treatment
ID Miklavčič, Damijan (Author), ID Cindrič, Helena (Author), ID Davalos, Rafael V. (Author), ID Deschamps, Frederic (Author), ID Gehl, Julie (Author), ID Kos, Bor (Author), ID Kramar, Peter (Author), ID Kuhelj, Dimitrij (Author), ID Meijerink, Martijn R. (Author), ID Soden, Declan M. (Author), ID Štabuc, Miha (Author), ID Serša, Gregor (Author)

.pdfPDF - Presentation file, Download (1,42 MB)
MD5: 313C88C42234DB4B4C568696011E2207
URLURL - Source URL, Visit https://reference-global.com/article/10.2478/raon-2026-0040 This link opens in a new window

Abstract
Background. Electroporation-Based Treatments and Therapies (EBTTs) – electrochemotherapy, irreversible electroporation, pulsed field ablation, and gene electro-transfer – use short, high-voltage electric pulses to permeabilize cell membranes, enabling non-thermal tissue ablation and enhanced local drug delivery. Although EBTTs have been used clinically for over three decades, primarily in oncology, their adoption remains limited compared to thermal ablation modalities. In contrast, cardiac pulsed field ablation (PFA) has seen rapid adoption since the first FDA device approval in December 2023. Conclusions. This expert opinion paper reviews the current clinical landscape of EBTTs in oncology and cardiac arrhythmia treatments, and focuses on emerging non-oncological and non-cardiac applications, including endoscopic pulsed electric field therapy for type 2 diabetes, bronchial rheoplasty for chronic bronchitis, bleomycin electrosclerotherapy for vascular malformations, nanosecond PFA for benign thyroid nodules, and electroporation-mediated gene delivery – and identifies key barriers to wider adoption: insufficient randomized evidence, lack of validated treatment planning tools, fragmented reimbursement, and limited standardization. We outline measures to facilitate clinical translation.

Language:English
Keywords:elektroporacija, ablacija s pulzirajočim poljem, elektrokemoterapija, ireverzibilna elektroporacije, genska elektrotransfekcija
Work type:Article
Typology:1.02 - Review Article
Organization:FE - Faculty of Electrical Engineering
Publication status:Published
Publication version:Version of Record
Publisher:Association of Radiology and Oncology
Year:2026
Number of pages:str. 319-322
Numbering:Vol. 60, no. 3
PID:20.500.12556/RUL-186665 This link opens in a new window
UDC:602.621
ISSN on article:1318-2099
DOI:10.2478/raon-2026-0040 This link opens in a new window
COBISS.SI-ID:287787523 This link opens in a new window
Publication date in RUL:04.09.2026
Views:61
Downloads:7
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Association of Radiology and Oncology
ISSN:1318-2099
COBISS.SI-ID:32649472 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:electroporation, pulsed field ablation, electrochemotherapy, irreversible electroporation, gene electrotransfer

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back